Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load

Yan, Li; Chen, En‐Qiang; Bai, Lan; Du, Lingyao; Chen, Lanlan; Liao, Juan; He, Min; Tang, Hong

doi:10.1016/j.clinre.2014.09.009

Cited by 8 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have found longer time to and lower rate of HBV DNA negativity in the subgroups of patients with e antigen positivity and higher baseline HBV DNA level [11,13,15,17], but others have not as in our study [18,19]. Studies have also found that previous NA exposure, age more than 60 years and the presence of cirrhosis do not influence viral suppression during prolonged therapy as our study [4,13,18,20].…”

Section: Discussioncontrasting

confidence: 59%

5-year efficacy of entecavir in Indian patients with chronic hepatitis B

Ray¹

2016

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 59%

5-year efficacy of entecavir in Indian patients with chronic hepatitis B

Ray¹

2016

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Except for the study conducted by Shi et al [19], no significant difference was observed in baseline HBeAg status and HBV DNA level between the two groups. Contrary to the general belief that high HBV DNA level is a predictor of poor response to antiviral treatment [23], Shi et al [19] found that the patients with CHB and hepatosteatosis had lower HBV DNA levels than the patients with CHB alone. This indicates that baseline HBV DNA level may not contribute to the response to treatment.…”

Section: Discussionmentioning

confidence: 96%

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Zhu

Yang

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. This study is to systematically analyze the effects of hepatosteatosis on the response to antiviral treatment in patients with chronic hepatitis B (CHB) and hepatosteatosis. Methods. Systematic search was performed in PubMed, Embase, Web of Science, Elsevier, and the Chinese BioMedical literature databases for relevant studies published until February 2016. Treatment outcomes were compared between patients with CHB plus concomitant hepatosteatosis and those without hepatosteatosis. Results. A total of 8 prospective cohort studies (399 patients with CHB plus hepatosteatosis and 688 patients with only CHB) were included. Biochemical and virological response at both 48 and 96 weeks were significantly lower in patients with CHB plus hepatosteatosis as compared to that in patients with only CHB. Subgroup analysis based on methods used for diagnosis of hepatosteatosis and treatment regimens showed that when hepatosteatosis was diagnosed on Doppler ultrasound and treated with nucleotide analogues, patients with CHB plus hepatosteatosis showed lower biochemical (62.7% versus 75.8%, P = 0.002) and virological response (66.2% versus 72.3%, P = 0.006) as compared to that in patients with CHB. Conclusion. Hepatosteatosis lowers the efficacy of antiviral treatment in patients with CHB, especially when hepatosteatosis was diagnosed on ultrasound findings and treated with nucleotide analogues.

show abstract

“…In this study, the HBV DNA cutoff was 12 IU/mL, the mean HBV DNA level was 6.5 ± 1.3 IU/mL, and HBeAg‐positive patients comprised 55% of the cohort. The virologic response to NUC therapy was poorer in patients with HBeAg‐positive status and high baseline HBV DNA levels . However, more importantly, MVR (persistently undetectable HBV DNA levels) is a time‐dependent variable that depends on the follow‐up period and interval of HBV DNA measurements.…”

Section: Discussionmentioning

confidence: 99%

“…The virologic response to NUC therapy was poorer in patients with HBeAgpositive status and high baseline HBV DNA levels. (23)(24)(25) However, more importantly, MVR (persistently undetectable HBV DNA levels) is a time-dependent variable that depends on the follow-up period and interval of HBV DNA measurements. The virological response can be assessed at specific time points (e.g., at week 48 or week 96).…”

Section: Discussionmentioning

confidence: 99%